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Abstract: 
Once tumor cells metastasize to the bone, the prognosis for prostate cancer patients is 
generally very poor. The mechanisms involved in bone metastasis, however, remain 
elusive, due to lack of relevant animal models. In this manuscript, we describe step-by-
step protocols for the xenograft mouse models that are currently used for studying 
prostate cancer bone metastasis. The different routes of tumor inoculation  (intraosseous, 
intracardiac, intravenous, orthotopic) presented are useful for exploring the biology of 
bone metastasis.  
 
  
Introduction: 
 
Prostate cancer is the second leading cause of cancer death in men in the US. Due to the 
recent improvement of treatment strategies for localized disease, a 5-year overall survival 
rate of over 90% has been achieved in prostate cancer patients 
(http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-survival-
rates). However, once cells spread to specific secondary organs such as bone, the 5-year 
survival rate of prostate cancer patients dramatically decreases to 28% 
(http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-survival-
rates). Aside from the poor prognosis, bone metastasis significantly impairs the quality of 
life of prostate cancer patients, since it is associated with myelophthisis, hypercalcemia, 
bone pain, fracture, and/or nerve compression. Therefore, there is an urgent need to 
understand the biology of bone metastasis in order to fight against this complex disease 
and its painful consequences. 
 
Prostate cancer is known as a heterogeneous tumor (1). For instance, some prostate 
cancers, when they disseminate to the bone, present both osteolytic and osteoblastic bone 
lesions, although bone metastasis from prostate cancer is classically classified as 
osteoblastic. In addition to tumor heterogeneity, bone marrow also contains 
heterogeneous populations, including hematopoietic lineage cells and cells regulating 
bone remodeling. The interaction between these bone marrow cells and cancer cells is 
thought to be important for cancer progression (2). This heterogeneous and complex 
organization makes revealing the mysterious bone metastatic properties of prostate cancer 
much more difficult. 
 
Metastasis involves multiple steps. First, tumor cells induce neovascularization 
(angiogenesis), acquire an invasive phenotype (epithelial mesenchymal transition), 
invade surrounding tissues (invasion), move into the circulation through the basal 
membrane (intravasation), travel throughout the body (circulation), and then adhere to a 
specific endothelium and disseminate into a secondary organ (extravasation). Once there, 
these disseminated tumor cells adapt to this new environment (colonization), survive for 
a long time without growing (dormancy), and eventually regrow (metastatic growth or 
recurrence). Since this extremely complicated metastatic process is impossible to recreate 
with an in vitro or ex vivo approach, and experiments with human are not reasonable, we 
need to rely on a pre-clinical approach with animal models to study bone metastasis. 
However, to date, there has been no ideal animal model that allows us to follow all these 
steps simultaneously. 
 
Recently, in vivo xenograft mouse models have been developed that involve intraosseous, 
intracardiac, intravenous, and orthotopic injections, which provide a means to better 
study prostate cancer bone metastasis. In this manuscript, we will provide details of the 
methods used in these animal models. 
 
 
 
 
Xenograft mouse models for studying prostate cancer bone metastasis 
Murine xenograft models are commonly used for experimental bone metastasis. Tumor 
growth in marrow is achieved through injection of human cancer cell lines via different 
routes.  
 
1. Preparation before prostate cancer cell inoculation 
 
Preparation of prostate cancer cell suspension  
 
Materials 
1. Prostate cancer cell lines. 
2. Tissue culture flasks or dishes. 
3. Appropriate antibiotics (e.g. Penicillin–Streptomycin). 
4. Culture medium supplemented with 10% fetal bovine serum (FBS) and 
antibiotics. 
5. 0.05% trypsin-EDTA. 
6. Sterile 1x Phosphate-buffered saline (PBS, pH=7.2-7.4). 
7. 70µm Cell Strainer. 
8. 15mL and 50mL sterile conical tubes. 
9. 0.4% Trypan blue. 
10. Hemacytometer or automated cell counter.  
11. Ca2+-free and Mg2+-free Hanks’ Balanced Salt Solution with Phenol Red 
Indicator (HBSS). 
 Procedures 
1. One day prior to inoculation, passage prostate cancer cells so they will be 70–
80% confluent on the day of the experiment. This ensures that cells are in the 
exponential growth phase, as recommended for optimal tumor onset. 
 
*NOTE: Prepare approximately 2-3 times more cells than you anticipate needing. 
 
*NOTE: Slow growing cells (e.g. LNCaP, LNCaP C4-2B, VCaP) may need to be 
passaged three-four days earlier. 
 
2. Trypsinize the cells, quench the trypsin activity by adding a sufficient 
volume of media containing FBS, and wash one or two times with 1xPBS. 
3. Filter cells through a 70μm cell strainer to exclude large cell aggregates.  
4. Count the total live and dead cell number, and determine the viability of the 
cells with trypan blue by using hemacytometer or automated cell counter. 
 
*NOTE: The viability of cells should be ≥ 90% prior to injection. 
 
5. Centrifuge the cells in a swinging bucket centrifuge at 100-400g for 3 
minutes. 
6. Carefully remove the media without disturbing the cell pellet.  
7. Re-suspend cells in an appropriate volume of HBSS.  
8. Transport cells to surgical room on ice. 
 
9. Draw the prepared cell suspensions into the syringe and push out any air 
bubbles that may exist.  
 
*NOTE: The number of cells for injection depends on the metastatic ability of the 
cell line and the experimental model. Usually, osteolytic prostate cancer cells 
require fewer cells to grow within the marrow (e.g. 2,500-500,000 cells), while 
osteoinductive prostate cancer cells need more cells (e.g. 500,000 cells). 
Recommended cell number and injection volume for different inoculation models 
are as follows: 
 
 Intraosseous inoculation: 0.25-5 x 104 cells/5-10μL 
 Intracardiac inoculation: 1-5 x105 cells/100μL 
 Intravenous inoculation: 1-5 x 106 cells/100μL 
 Orthotopic inoculation: 1-5 x 104 cells/10μL 
 
*NOTE: Set-up the experiment keeping time from harvest to injection at a 
minimum, to assure the cells stay alive throughout the injection process. The 
viability of cells will decline with time. At the end of an injection experiment, the 
cell viability should be above 80%.  
  
Preparation for Surgery  
 
Materials 
1. Animals: Depending on the prostate cancer cell line to be inoculated, 
immunodeficient mice (BALB/c nu/nu, CB17 SCID) are used. Animals should be 
between 4 and 8 weeks old. 
2. Isoflurane 
3. Ketamine 
4. Xylazine 
5. Eye ointment (Vitamin A) 
6. Shaver or chemical hair remover 
7. Warming pad 
 
Procedures 
1. Set-up the laminar flow with all necessary equipment and materials (Figure 
1A&B). 
 
*NOTE: Surgery should be conducted under aseptic conditions and use sterile 
instruments, supplies, and wound closure materials within a designated surgical room, 
and following procedures approved by the facility department of animal care 
oversight.  
 
2. Anesthetize animals if necessary. 
 This anesthesia should be performed only if equipped with a proper 
ventilated area. 2% isoflurane mixed with 98% oxygen in the induction 
chamber. Mice should be kept under anesthesiafor the duration of the 
surgery by being placed on their back and their head (nose) inserted into 
the breathing tube.  
 Alternatively, xylazine–ketamine cocktail (Ketamine (100mg/mL) : 
Xylazine (20mg/mL) : 1xPBS = 3 : 2 : 5), can be administered 300μL per 
1kg body weight intraperitoneally (i.p.) 
3. Monitor animals until fully anesthetized (loss of reflexes) and place them on a 
warming pad. 
 
*NOTE: Prior to surgery, depth of anesthesia should be ensured by gently pinching 
the hind paw or tail tip. Mice should be unresponsive. If there is a response 
(movement) wait longer or (in the case of ketamine injection) administer another 
small dose. Please consult with your local authority, as the regulation may vary. 
 
4. Apply ophthalmic ointment, and remove the hair if necessary. 
5. Place the animal in an appropriate position (e.g. supine or prone) on a heated 
operation table within the laminar flow. 
6. Disinfect the surgical area with 70% ethanol. 
  
2. Prostate cancer cell inoculation routes 
 
Intraosseous inoculation (Written by JH) 
 
Materials  
1. Sterile 1xPBS 
2. Dental drill (power supply and drill, www.proxxon.com) and dental needles 
(Hedstroem files 28mm/30) 
3. Surgical scissors, tweezers, scalpel and blade 
4. Cotton swabs 
5. 70% ethanol gauze  
6. 1 mL syringes with a 27G needle  
7. 0.5 or 1mL Insulin syringes (30G, ½ inch) 
8. Surgical bone wax (Ethicon), capillary pistons (CP25, Gilson Microman) and 
spatula (Figure 2A) 
9. Suturing thread  
10. Betadine®  
11. Faxitron radiography system (MX-20, Faxitron X-Ray Corporation)  
 
Procedures 
 Intratibial injection (Method 1): 
1. Place the animal in supine position on a heated operation table within the 
laminar flow (administer anesthesia as indicated above). 
2. Disinfect the hind limb with 70% ethanol. 
3. Flex the knee at about 90-degree angle. 
4. Insert a 27G needle into the joint surface through the patellar tendon and tibial 
plateau in order to enter the intramedullary canal of the tibia.  
 
*NOTE:  The needle should be inserted with a drilling movement. Alternatively, an 
incision over the patellar tendon, followed by a longitudinal arthrotomy along the 
medial border of the patellar tendon can be performed to expose the tibial plateau.  
 
5. Inject the cancer cell suspension with a 30G needle via the proximal hole 
(10μL maximal volume, but less volume would be ideal). 
6. Inject an appropriate analgesic and monitor mice until they fully recover. 
 
*NOTE:  Alternatively to this method a needle can be used to drill a hole proximal to 
the tibial tuberosity. After penetration of the cortical bone the cancer cell suspension 
can be injected. 
 
*NOTE:  To migrate out of the medullary cavity, bone marrow ablation creates space 
for the injection and drilled holes can be sealed with bone wax preventing cancer cells 
(Please see Method 2). 
 
 
 
Intraosseous inoculation (Method 2):  
 
1. Place the animal in supine position on a heated operation table within the 
laminar flow (administer anesthesia as indicated above). 
 
*NOTE: Tape the animal’s hind limb to the operation table (if the leg is tape-fixed 
over a needle cap with a rotation to the inner side, drilling of the holes is facilitated) 
(Figure 2B&C). 
 
2. Disinfect the hind limb with 70% ethanol. 
3. Make a skin incision with a scalpel starting slightly below the knee joint to the 
end of the tibial bone marrow cavity (Figure 2D). 
 
NOTE: Take care to not damage the tibial vein or artery. 
 
4. Carefully resect the caput mediale of the gastrocnemius along the anterior 
tibial margin, then continue to resect its insertion on the medial surface of the 
tibia to uncover the underlying bone. 
5. Constantly apply 1xPBS to prevent drying of the wound. 
6. Drill two holes, one in close proximity to the metaphyseal growth plate and 
one at the distal end of the tibial bone marrow cavity (Figure 2D: arrows 
indicate the position of holes to be drilled; Figure 2E: arrows indicate 
position of drilled holes as seen on radiographs). 
 *NOTE: The dental drill bit should be held perpendicular to the tibia while drilling 
 
7. Flush the bone marrow with 0.5mL 1xPBS using a 30G needle. 
8. Insert bone wax with a capillary piston into the distal hole and press with a 
spatula. 
9. Inoculate the cancer cell suspension intra-medullarily with a 30G needle via 
the proximal hole (10μL maximal volume, but less volume would be ideal).  
10. Seal the proximal hole with bone wax and suture the wound with 2-3 stitches. 
11. Disinfect the wound with betadine. 
12. Inject an appropriate analgesic and monitor mice until they fully recover. 
 
*NOTE:  Both Method 1 and Method 2 are invasive.  Either the injection channel 
using Method 1 or the drilled holes using Method 2 will be identified in histological 
sections. The injection volume has to be kept minimal for both methods due to the 
space limitation in the medullary cavity.  
 
*NOTE: Mice should be monitored regularly, according to an approved mouse 
protocol, and sacrified if clinical signs match the experimental endpoint. Signs 
include, but are not limited to: rapid weight loss, any condition interfering with daily 
activities (e.g. eating or drinking, ambulation, or elimination). 
 
*NOTE: Bone lesions can be monitored by radiography (Faxitron, 25kV, 6s) (Figure 
3A&B: representative radiography pictures of osteolytic and osteoblastic bone 
metastases), and cancer cell growth can be monitored using bioluminescence imaging 
(only for luciferase-labeled cells). 
 
  
Intracardiac inoculation (Written by NW) 
 
Materials  
1. 70% ethanol gauze  
2. 0.5 or 1mL Insulin syringes (30G, ½ inch) 
 
Procedures 
1. Hold the syringe with thumb, index finger and middle finger. Ring finger and 
little finger are used to withdraw and push the plunger, respectively (Figure 
4A).  
2. Use thumb and index finger of the other hand to slightly squeeze the rib cage 
of mouse from dorsal side upward to raise the position of the heart (Figure 4B) 
(administer anesthesia as indicated above). 
3. Disinfect the chest area with 70% ethanol.  
4. Insert needle horizontally into the injection point and slightly withdraw the 
plunger after the needle has been inserted 7-8 mm. 
 
*NOTE: Push and withdraw the plunger of syringe several time to reduce friction 
force before loading the syringe with 120μL cell suspensions (20μL in excess). 
 
*NOTE: Alternatively, needle can be inserted vertically. 
  
*NOTE: Injection point is 1-2 mm left of the midline and 1-2 mm beneath the edge 
of rib cage of the mouse (Figure 4C). 
 
*NOTE: If the needle is properly inserted in the left ventricle, bright-red blood will 
be pumped back into the cell suspension and pulsation should be visible from the air 
bubble remaining in the syringe (Figure 4D). If there is no blood pumping back or 
dark-red blood observed, retract and re-insert the needle, but no more than 3 attempts 
should be done within 24 h. 
 
5. Inject the cell suspension at a slow pace (approximately 30 sec for total 
100µL).  
 
*NOTE: Avoid positional change of injecting hand during injection.  
 
*NOTE: Correct injection can be verified during the process of injection by the color 
of blood pumped back to syringe. Should the needle be correctly injected into the left 
ventricle, bright-red, oxygenated arterial blood will be seen, which is distinctive from 
the darker venous blood of the right ventricle (Figure 5A). 
 
*NOTE: Tumor cells in the systemic circulation can also be verified within 24 h after 
injection by bioluminescence imaging, if you are using luciferase-labeled cells. If 
tumor cells are correctly injected into the left heart ventricle, bioluminescence signals 
can be observed in the whole body (Figure 5B). Otherwise, signals will be 
concentrated in the chest area, and resemble the shape of lung, or will be completely 
absent (Figure 5C). 
 
6. Slightly withdraw the plunger during the inoculation, and observe whether 
blood is still pumping back into the syringe to confirm that the needle is still 
placed in the left ventricle. 
7. Complete the injection of 100µL of cell suspension with the 20μL excess 
remaining in the syringe. Wait for 5 sec before the needle is taken out.  
8. Monitor mice until they fully recover. 
 
*NOTE: After the successful injection, the mouse is placed back into a clean cage on 
a heating pad, until fully recovered from the anesthesia. Closely monitor the mouse 
for the first 24 h after injection. 
 
 
 
  
Intravenous inoculation (Written by JD) 
 
Materials 
12.       Mouse restrainers 
13. 70% ethanol gauze  
14. 1mL syringes with 26-28G needle, ½ inch 
 
*NOTE: Various mouse restrainers are available, but the mouse tail illuminator 
restrainer from Braintree Scientific, Inc is recommended, because it efficiently 
illuminates and warms a mouse tail for easy injection. 
 
Procedures 
1. Gently grab the tail of a mouse and pull it into the commercial or custom 
mouse restrainer, with its back against the slit and its tail sticking out of the 
small opening in the back of the restrainer. Slowly close doors and keep 
mouse gently restrained. 
2. Find the lateral tail vein (Figure 6) and promote vasodilation of the vein for 
easy injection by warming the mouse using a heat lamp or warming device, or 
by immersion of the tail in warm water for about 5 min.  
 
*NOTE: The time will be dependent on the distance from the heat source, and the 
animals must be monitored carefully to prevent being burned or overheated by the 
heat source.  
 3. Disinfect the tail with 70% ethanol.  
4. Pull the tail straight.  
5. Hold the tip of tail with thumb, and support the point for injection with the 
index finger.  
6. With the bevel facing up, insert a needle into one of the lateral tail veins in the 
proximal 1/3 of the tail, and gently inject 100µL of the cell suspension.  
 
*NOTE: A successful injection is based on lack of resistance while pushing the 
plunger. 
 
*NOTE: Start from the distal end of the tail, so if the first trial fails, a more proximal 
region of the tail can be used if another attempt is needed. 
 
*NOTE: The maximum volume that may be injected depends on numerous factors, 
including the mouse’s size, background strain, and properties of the cells. Most users 
try to limit the injection to a maximum of 0.25mL. Keep in mind that over-
concentration of cells may lead to embolism in lung capillaries and death of the mice. 
  
7. Withdraw the needle after injection and press a clean piece of paper towel or 
cotton swab on the injection site to facilitate clotting. 
8. Release the mouse from the restrainer and return it to the cage.  
 
*NOTE: Most mice show only reduced activity levels. The mice should be observed 
for the first hour following injection. If no problems are observed other than reduced 
activity, the mice may be returned to standard housing.  
 
 
  
Orthotopic inoculation (Written by MKJ) 
 
Materials 
1. Sterile 1xPBS 
1. Surgical scissors and tweezers  
2. Cotton swabs 
3. 70% ethanol gauze  
4. 0.5 or 1mL Insulin syringes (30G, ½ inch) 
5. Suturing thread (would clip is not ideal for imaging) 
6. Betadine®  
 
Procedure 
1. Place a mouse in supine position, immobilization is not necessary (administer 
anesthesia as indicated above). 
2. Disinfect the lower abdomen with 70% ethanol.  
3. Make a small (1cm) incision in the lower midline of the peritoneum. 
4. Exteriorize and gently stabilize the prostate dorsal lobes with a wet (1xPBS) 
cotton swab (Figure 7).  
5. Insert the needle into the right dorsal lobe of the prostate at a 45-degree angle. 
6. Slowly inject 10µl of the cell suspension.  
 
*NOTE: A well-localized bleb indicates a successful injection. 
 
7. Retract the needle gently and place a cotton swab over the injection site for 
about 1 min to prevent bleeding and spillage of material.  
8. Return the prostate to the peritoneum and suture the abdominal wall first and 
the skin layer after with a 4-0 silk suture.   
9. Disinfect the wound with betadine. 
10. Inject an appropriate analgesic and monitor mice until they fully recover. 
 
*NOTE: Mice should be monitored regulary according to an approved mouse 
protocol and sacrified if clinical signs match experimental endpoint. Signs include but 
are not limited to: rapid weight loss, any condition interfering with daily activities 
(e.g. eating or drinking, ambulation, or elimination). 
 
 
  
3. In vivo bioluminescence imaging 
 
Materials 
1. Luciferase-labeled prostate cancer cell line (PCa-luc cells). 
 
*NOTE: Luciferase-labeled prostate cancer cells are greatly useful to follow 
metastasis in vivo. Lentiviral transfer of luciferase gene and subsequent selection and 
verification of stable clones should be performed in advance. Luciferase-labeled PC-3 
cells can be purchased from Caliper Life Sciences or generated individually by 
transducing cells with lentiviral vectors and luciferase reporter vectors (pGL4 
Luciferase Reporter Vectors from Promega). Verify luciferase activity in cells before 
injection. 
 
2. Sterile 1xPBS 
3. 1 mL syringes with a 25G needle  
4. D-Luciferin (from Regis, or Caliper or Promega) 
5. Isoflurane 
6. Oxygen tank 
7. Isoflurane/oxygen-based anesthesia system fitted with an induction 
chamber and inhalation masks for mice 
 
*NOTE: Xylazine–ketamine cocktail can be used if no Isoflurane/oxygen-based 
anesthesia system available.  
 8. In vivo imaging system (IVIS, Xenogen/Perkin-Elmer). 
 
Procedure 
1. Prepare a sterile stock solution of D-luciferin in 1xPBS (40mg/mL). 
2. Inject 150μg/g D-luciferin into the intraperitoneal cavity of mice, using a 
syringe with a 25G needle. 
3. Initialize the ‘Living Image’ software provided by the manufacturer on a 
computer attached to the IVIS machine. 
4. Set exposure time and imaging parameters. 
5. Anesthetize the mice in 2% isoflurane mixed with 98% oxygen in induction 
chamber. 
6. Place mice in the IVIS platform while keeping mice under anesthesia 
through a nose cone, and take the image 12 min after D-luciferin injection. 
 
*NOTE: It is recommended to perform an initial kinetic experiment for each 
animal model taking images during different time points. This will allow you to 
determine the D-luciferin distribution for your experiment. 
 
7. Analyze and quantify the photons emitted from luciferase-labeled cells 
within the animal according to the manufacturer’s protocol. 
 
*NOTE: For the intravenous inoculation model of prostate cancer, a highly 
metastatic cancer cell line (e.g. PC-3 and DU145) typically gives rise to many 
metastases, especially at hind limb with bone metastatic lesions (Figure 8A), while 
very few metastases will be detected from a poorly metastatic cancer cell lines 
(e.g. LNCaP and LNCaP C4-2B). 
 
*NOTE: Bioluminescence is a well-established technique commonly utilized to track 
tumor growth, and to locate and monitor the presence of metastases within living 
animals. In vivo bioluminescence imaging system is a highly sensitive imaging 
technology to quantify bioluminescence via a digital camera and advanced computer 
software. This system detects photons emitted from luciferase-expressing cells within 
the living animals.  
 
*NOTE: In certain cases, it may be important to get both dorsal and ventral images. 
 
*NOTE: Many imaging techniques can also be used to detect the prostate cancer 
metastatic lesions in mice, such as molecular imaging techniques or small-animal 
diagnostic imaging (microcomputed tomography or magnetic resonance imaging or 
Faxitron cabinet x-ray systems) (Figure 8B). If both bioluminescence and other 
imaging techniques are not available, histopathological examination of metastatic 
nodules subsequent to necropsy is the best approach. 
 
  
Discussions/Conclusion: 
 
In this manuscript, we discussed the mouse xenograft models that are commonly used to 
study prostate cancer bone metastasis. Using these models with human prostate cancer 
cell lines (Table 1) (3-28), we have gained a greater understanding of the process of bone 
metastasis. However, there are limitations for using these xenograft models, since the 
immune systems of animals used for developing these models are weak or compromised 
to avoid an immune response to the human tissue. There are currently some transgenic 
spontaneous prostate cancer models, which may overcome this limitation, however the 
transgenic mice currently available rarely result in bone metastases, unlike that seen in 
human prostate cancer (29). Although humanized animal models (30, 31) or ex vivo 
tissue engineered models (32, 33) have been recently proposed to potentially mimic bone 
metastasis, models that perfectly recapitulate the human prostate cancer bone metastatic 
process are still missing. To unveil the mystery of bone metastasis, further improvement 
of animal models currently available and/or development of new animal models to 
overcome the limitations that we are facing are clearly warranted.  
  
Figure Legends: 
 
Figure 1: An example images for sterile surgical suite 
(A, B) laminar flow with mounted microscope, heated operation table, and necessary 
equipment. 
 
Figure 2: Intraosseous inoculation of prostate caner cells  
(A) Capillary piston, bone wax, and spatula. (B, C) Fixation of hind limb. Gently grab the 
hindlimb of the animal with a tweezer to avoid damaging to a mouse foot and tape it to 
the operation table. (D) Skin incision, white arrows point to the position of holes to be 
drilled. (E) Radiograph of tibia after intraosseous inoculation (white arrows point to the 
drilled holes).  
 
Figure 3: Representative radiographs after intraosseous inoculation  
Representative images of radiographs after the intraosseous injection of (A) osteolytic 
prostate cancers cells (PC-3) into the bone marrow cavity of CB17 SCID mice (Day 32, 
2,500 cells delivered) and (B) osteoinductive prostate cancer cells (VCaP) into the bone 
marrow cavity of CB17 SCID mice (Day 91, 500,000 cells delivered). 
 
Figure 4: Intracardiac inoculation of prostate cancer cells 
(A) Properly holding of the syringe. Thumb, index finger and middle finger are used to 
hold the syringe while ring finger and little finger are responsible for withdrawing and 
pushing the plunger. (B) Mouse is placed in a supine position and the rib cage is 
squeezed up to raise the position of the heart. (C) Insert the needle horizontally into the 
injection point 1-2 mm left of the midline (the dotted line) and 1-2 mm beneath the edge 
of rib cage (the solid line). The approximate position of the heart is marked in red. (D) 
When the needle is successfully inserted into the left ventricle, slightly withdrawing the 
plunger will pump bright-red blood back into the cell suspension in the syringe (yellow 
arrow).  
 
Figure 5: Verification after intracardiac inoculation 
(A) Bright-red, oxygenated arterial blood from correct injection into the left ventricle (L) 
and darker venous blood of the right ventricle from incorrect injection (R). 
Representative images of in vivo bioluminescence imaging within 24 h after injection (B) 
in the correctly injected mouse (whole body bioluminescence signals) and (C) in the 
incorrectly injected mouse (lung-shape signals over thorax).  
 
Figure 6: Anatomy of murine tail 
Murine tail veins are found in both sides of murine tail (just under the skin). Intravenous 
injections should be performed via the lateral tail vein. 
 
Figure 7: Orthotopic inoculation of prostate cancer cells 
The prostate dorsal lobes are gently exteriorized, and prostate cancer cells will be 
inoculated.  
 
Figure 8: Representative images after intravenous injection 
Representative images of (A) in vivo bioluminescence imaging and (B) radiograph after 
the intravenous injection of luciferase-labeled PC-3 cells into a nude mouse. Multiple 
bone metastatic lesions are detected at mouse hind limbs.  
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